financetom
Business
financetom
/
Business
/
Elon Musk is planning on taking CEO role at twitter: Reports
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Elon Musk is planning on taking CEO role at twitter: Reports
Oct 28, 2022 1:46 AM

After closing the $44 billion deal to take over Twitter, Elon Musk is all set to take over the role of the chief executive officer at the microblogging website, as reported by Bloomberg.

The news comes a few hours after the reports stating that Musk has fired the social media company’s four top executives, including Indian-origin CEO Parag Agrawal and legal executive Vijaya Gadde.

Bloomberg also reported that Musk is planning to reverse lifetime bans on users.

Earlier in the day, Musk hinted at being the company's top boss after updating his profile's bio to "Chief Twit".

One of the interesting aspects of the whole firing fiasco is that this move comes a day after Musk denied the reports claiming that after closing the deal Musk will resort to mass layoff, which will amount to 75 percent of Twitter employees.

Also read: As the epic Twitter deal nears closure, what are Elon Musk’s plans for the platform?

The billionaire said he paid a visit to Twitter Inc's headquarters in San Francisco on Wednesday, ahead of a court-ordered deadline to close his $44 billion deal for the social media platform.

"Entering Twitter HQ – let that sink in!" said the caption of a video that Musk tweeted in which he was walking into the Twitter office carrying a sink in his hands.

After the reports of the firings at Twitter, Musk shared a tweet saying: "The bird is freed".

Also read: Twitter CEO Parag Agarwal may get $42 million payout as he gets terminated by Musk

First Published:Oct 28, 2022 10:46 AM IST

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
O-I Glass to Invest $65 Million in Electrification, Decarbonization Project for Plant in France
O-I Glass to Invest $65 Million in Electrification, Decarbonization Project for Plant in France
Jun 18, 2024
10:34 AM EDT, 06/18/2024 (MT Newswires) -- O-I Glass ( OI ) said Tuesday it plans to invest about $65 million into the electrification and decarbonization of its plant in Veauche, France. The company said one of its two furnaces will be renovated and fitted with hybrid-flex technology. The project will give the company the flexibility to replace up to...
JAKKS Pacific's Disguise Unit Signs Multi-Year Licensing Deal With Aniplex of America
JAKKS Pacific's Disguise Unit Signs Multi-Year Licensing Deal With Aniplex of America
Jun 18, 2024
10:37 AM EDT, 06/18/2024 (MT Newswires) -- JAKKS Pacific's ( JAKK ) Disguise business unit said Tuesday that it signed a multi-year licensing agreement with Aniplex of America covering the Demon Slayer: Kimetsu no Yaiba animated series in North America, Australia, New Zealand, LATAM, Ireland, and the UK. The deal allows Disguise to design, develop, and manufacture costume accessories based...
Canadian Imperial Bank Of Commerce, Bank of Nova Scotia, Bank of Montreal Ratings Affirmed by Fitch
Canadian Imperial Bank Of Commerce, Bank of Nova Scotia, Bank of Montreal Ratings Affirmed by Fitch
Jun 18, 2024
10:37 AM EDT, 06/18/2024 (MT Newswires) -- Fitch Ratings has affirmed the long-term issuer default rating and short-term issuer default rating on Canadian Imperial Bank Of Commerce's ( CM ) , Bank of Nova Scotia's ( BNS ) , and Bank of Montreal's ( NRGD ) at AA- and F1+, respectively. Also, Fitch affirmed the ratings of the bank's subsidiaries...
Intra-Cellular Therapies' Highlights Successful Data From Second Depression Study
Intra-Cellular Therapies' Highlights Successful Data From Second Depression Study
Jun 18, 2024
Tuesday, Intra-Cellular Therapies Inc ( ITCI ) released topline results from Study 502 evaluating lumateperone 42 mg as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD).  The company expects to submit a supplemental FDA application in the second half of 2024. Lumateperone 42 mg, given once daily as adjunctive therapy to antidepressants, met the primary...
Copyright 2023-2026 - www.financetom.com All Rights Reserved